MedPath

AK119

Generic Name
AK119
Drug Type
Biotech
Background

AK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).

Clinical Trials
Related News

A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

First Posted Date
2023-05-06
Last Posted Date
2025-03-03
Lead Sponsor
Akeso
Target Recruit Count
170
Registration Number
NCT05846867
Locations
🇨🇳

Cancer Hospital Affiliated to Harbin Medical University, Harbin, China

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor, Adult
Interventions
First Posted Date
2023-01-19
Last Posted Date
2023-04-20
Lead Sponsor
Akeso
Target Recruit Count
87
Registration Number
NCT05689853
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Phase 1
Recruiting
Conditions
NSCLC
Interventions
First Posted Date
2022-12-05
Last Posted Date
2023-03-09
Lead Sponsor
Akeso
Target Recruit Count
114
Registration Number
NCT05636267
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, China

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Solid Tumor, Adult
Interventions
First Posted Date
2022-09-29
Last Posted Date
2025-02-19
Lead Sponsor
Akeso
Target Recruit Count
33
Registration Number
NCT05559541
Locations
🇨🇳

Tianjin Medical University Cancer Insitute & Hospital, Tianjin, Tianjin, China

Study of AK119 in Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Solid Tumor
Interventions
First Posted Date
2021-12-30
Last Posted Date
2024-04-25
Lead Sponsor
Akeso
Target Recruit Count
16
Registration Number
NCT05173792
Locations
🇨🇳

Fudan University Zhongshan Hospital, Shanghai, China

🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced or Metastatic Solid Tumors
Interventions
First Posted Date
2020-10-01
Last Posted Date
2025-02-28
Lead Sponsor
Akeso
Target Recruit Count
23
Registration Number
NCT04572152
Locations
🇦🇺

Monash Health, Clayton, Victoria, Australia

🇦🇺

Alfred Health (The Alfred Hospital), Melbourne, Victoria, Australia

🇦🇺

Ashford Cancer Centre, Adelaide, South Australia, Australia

and more 2 locations

A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

Phase 1
Completed
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Drug: Placebo
First Posted Date
2020-08-18
Last Posted Date
2025-02-28
Lead Sponsor
Akesobio Australia Pty Ltd
Target Recruit Count
29
Registration Number
NCT04516564
Locations
🇳🇿

Christchurch Clinical Studies Trust, Christchurch, New Zealand

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy